Hepatitis B/D: Controversies in Diagnosis, Natural History and Treatment
Nov
13
2023
Ballroom BC
-
Hynes Convention Center
2:00
- 3:30 PM EST
Speakers
Description
Abstracts
- CONTINUED TREATMENT OF EARLY VIROLOGIC NON-RESPONDER OR PARTIAL RESPONDERS WITH BULEVIRTIDE MONOTHERAPY FOR CHRONIC HEPATITIS D LEADS TO IMPROVEMENT IN VIROLOGIC AND BIOCHEMICAL RESPONSES: RESULTS FROM AN INTEGRATED ANALYSIS AT WEEK 96
- IMMEDIATE POSTPARTUM CESSATION OF TENOFOVIR IN HIGHLY VIREMIC PREGNANT MOTHERS WITH CHRONIC HEPATITIS B INFECTION: MATERNAL AND INFANT OUTCOMES
- HEPATOCELLULAR CARCINOMA RISK IN SUB-SAHARAN AFRICAN AND AFRO-SURINAMESE INDIVIDUALS LIVING WITH CHRONIC HEPATITIS B IN EUROPE: AN INTERNATIONAL MULTICENTER RETROSPECTIVE COHORT STUDY
- TENOFOVIR VERSUS ENTECAVIR IN PREVENTING HCC AND DEATH: ANSWER FROM A LARGE INTEGRATED HEALTH PLAN POPULATION
- AN OPEN-LABEL ROLLOVER STUDY FOLLOWING A RANDOMIZED TRIAL FOR CHRONIC HEPATITIS B WITH HIGH SERUM VIRAL LOAD BUT MILD ELEVATED AMINOTRANSFERASE